Deutsche Bank Ag\ Biond Vax Pharmaceuticals Ltd. Transaction History

Deutsche Bank Ag\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$2.5 - $40.97 $812 - $13,315	-325 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$23.7 - $51.1 $7,702 - $16,607	325 New	325 $13,000
Q1 2020 May 14, 2020	SELL	$5.36 - $11.65 $1,072 - $2,330	-200 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.38 - $9.29 $1,614 - $2,786	-300 Reduced 60.0%	200 $1,000
Q3 2019 Nov 14, 2019	BUY	$5.43 - $6.71 $2,715 - $3,355	500 New	500 $2,000
Q2 2019 Aug 14, 2019	SELL	$5.43 - $7.19 $543 - $719	-100 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$4.76 - $5.8 $476 - $580	100 New	100 $0
Q4 2018 Feb 14, 2019	SELL	$3.97 - $5.99 $10,322 - $15,574	-2,600 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$5.5 - $6.78 $22,000 - $27,120	-4,000 Reduced 60.61%	2,600 $14,000
Q2 2018 Aug 14, 2018	SELL	$5.55 - $6.93 $19,980 - $24,948	-3,600 Reduced 35.29%	6,600 $44,000
Q1 2018 May 15, 2018	SELL	$5.43 - $7.49 $139,474 - $192,388	-25,686 Reduced 71.58%	10,200 $55,000
Q4 2017 Feb 14, 2018	BUY	$4.73 - $7.78 $42,503 - $69,911	8,986 Added 33.41%	35,886 $192,000
Q3 2017 Nov 14, 2017	BUY	$6.67 - $8.39 $179,423 - $225,691	26,900	26,900 $192,000

Ticker BVXV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,678,800
Market Cap $12M
Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Götting...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.